A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Active:	Yes
Cancer Type:	Unknown Primary Uterine Cancer	NCT ID:	NCT04814108
Trial Phases:	Phase II	Protocol IDs:	ZN-c3-004 (primary) NCI-2021-11201
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT04814108

Summary

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3
(azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

Objectives

This is a Phase 2 open-label, multicenter study to evaluate the clinical activity and
safety of ZN-c3 (also known as azenosertib; KP-2638) in adult women with recurrent or
persistent uterine serous carcinoma (USC).

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.